Delving into the Latest Updates on Beijing Huili Technology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Beijing HuiLi Technology Co., Ltd. is committed to the fields of pharmaceutical innovation, providing technical assistance, facilitating technology transfers, and offering technical services. The company has established collaborative partnerships with certain institutes within the Chinese Academy of Sciences as well as with prominent pharmaceutical corporations and is actively working towards the creation of an integrated platform for medical research and development services.

Tags

Other Diseases

Nervous System Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

SCNA(Sodium voltage-gated channel alpha subunits)	1

[Translation] A multicenter, randomized, double-blind, parallel, positive-controlled, dose-finding phase II clinical trial to evaluate the efficacy and safety of local infiltration of ropivacaine sustained-release microspheres for injection (RF16001) for postoperative analgesia after hemorrhoidectomy

主要目的： 1)评估罗哌卡因缓释微球用于痔切除术后镇痛的疗效；次要目的： 1)评估罗哌卡因缓释微球用于痔切除术后镇痛的安全性； 2)评估罗哌卡因缓释微球在痔切除术患者中的药代动力学特征； 3)探索罗哌卡因缓释微球药用于痔切除术后镇痛的合适剂量。

[Translation]

Main purpose: 1) To evaluate the efficacy of ropivacaine sustained-release microspheres for postoperative analgesia after hemorrhoidectomy; Secondary purpose: 1) To evaluate the safety of ropivacaine sustained-release microspheres for postoperative analgesia after hemorrhoidectomy; 2) To evaluate the pharmacokinetic characteristics of ropivacaine sustained-release microspheres in patients undergoing hemorrhoidectomy; 3) To explore the appropriate dose of ropivacaine sustained-release microspheres for postoperative analgesia after hemorrhoidectomy.

Start Date10 Sep 2024

Sponsor / Collaborator

Beijing Huili Technology Co., Ltd.

[+2]

CTR20233870

/ CompletedPhase 2

评价注射用罗哌卡因缓释微球（RF16001）局部浸润用于痔切除术后镇痛的有效性、安全耐受性、药代动力学的多中心、随机、双盲、阳性及安慰剂对照、剂量递增及剂量探索Ⅱ期临床试验

[Translation] A multicenter, randomized, double-blind, positive and placebo-controlled, dose-escalation and dose-finding phase II clinical trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of local infiltration of ropivacaine sustained-release microspheres for injection (RF16001) for postoperative analgesia after hemorrhoidectomy

主要目的： 1)评估罗哌卡因缓释微球用于痔切除术后镇痛的有效性；次要目的： 1)评估罗哌卡因缓释微球用于痔切除术后镇痛的安全耐受性； 2)评估罗哌卡因缓释微球在痔切除术患者中的药代动力学特征； 3)探索罗哌卡因缓释微球药用于痔切除术后镇痛的合适剂量。

[Translation]

Main purpose: 1) To evaluate the effectiveness of ropivacaine sustained-release microspheres for postoperative analgesia after hemorrhoidectomy; Secondary purpose: 1) To evaluate the safety and tolerability of ropivacaine sustained-release microspheres for postoperative analgesia after hemorrhoidectomy; 2) To evaluate the pharmacokinetic characteristics of ropivacaine sustained-release microspheres in patients undergoing hemorrhoidectomy; 3) To explore the appropriate dose of ropivacaine sustained-release microspheres for postoperative analgesia after hemorrhoidectomy.

Start Date04 Jan 2024

Sponsor / Collaborator

Beijing Huili Technology Co., Ltd.

[+2]

CTR20221476

/ TerminatedPhase 1

中国健康受试者单点局部浸润注射注射用RF16001的耐受性、药代动力学及药效学I期临床试验

[Translation] Phase I clinical trial of tolerability, pharmacokinetics and pharmacodynamics of RF16001 for injection in healthy Chinese subjects by single-site local infiltration injection

主要研究目的：评价健康受试者单点局部浸润注射不同剂量的注射用RF16001及盐酸罗哌卡因注射液的安全性和耐受性,评价健康受试者单点局部浸润注射注射用RF16001及盐酸罗哌卡因注射液的PD特征次要研究目的：评价健康受试者单点局部浸润注射不同剂量的注射用RF16001及盐酸罗哌卡因注射液的药代动力学（PK）特征,评价健康受试者单点局部浸润注射不同剂量的注射用RF16001及盐酸罗哌卡因注射液的安全性和耐受性探索性目的:探索健康受试者单点局部浸润注射不同剂量的注射用RF16001及盐酸罗哌卡因注射液的药效学（PD）特征

[Translation]

Main study objectives: To evaluate the safety and tolerability of single-point local infiltration injection of different doses of RF16001 and ropivacaine hydrochloride injection in healthy subjects, and to evaluate the PD characteristics of single-point local infiltration injection of RF16001 and ropivacaine hydrochloride injection in healthy subjects Secondary study objectives: To evaluate the pharmacokinetic (PK) characteristics of single-point local infiltration injection of different doses of RF16001 and ropivacaine hydrochloride injection in healthy subjects, and to evaluate the safety and tolerability of single-point local infiltration injection of different doses of RF16001 and ropivacaine hydrochloride injection in healthy subjects Exploratory objectives: To explore the pharmacodynamic (PD) characteristics of single-point local infiltration injection of different doses of RF16001 and ropivacaine hydrochloride injection in healthy subjects

Start Date27 Jun 2022

Sponsor / Collaborator

Beijing Huili Technology Co., Ltd.

[+2]

100 Clinical Results associated with Beijing Huili Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Huili Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Huili Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Huili Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Phase 2 Clinical

Login to view more data